- Home
- RSLS vs ALLR Comparison
RSLS vs ALLR Comparison
Compare RSLS & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- ALLR
- Stock Information
- Founded
- RSLS 2002
- ALLR 2004
- Country
- RSLS United States
- ALLR United States
- Employees
- RSLS N/A
- ALLR N/A
- Industry
- RSLS Medical/Dental Instruments
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- RSLS Health Care
- ALLR Health Care
- Exchange
- RSLS Nasdaq
- ALLR Nasdaq
- Market Cap
- RSLS 4.5M
- ALLR 4.0M
- IPO Year
- RSLS 2007
- ALLR N/A
- Fundamental
- Price
- RSLS $6.66
- ALLR $1.05
- Analyst Decision
- RSLS Hold
- ALLR
- Analyst Count
- RSLS 1
- ALLR 0
- Target Price
- RSLS N/A
- ALLR N/A
- AVG Volume (30 Days)
- RSLS 17.0M
- ALLR 1.1M
- Earning Date
- RSLS 05-19-2025
- ALLR 05-20-2025
- Dividend Yield
- RSLS N/A
- ALLR N/A
- EPS Growth
- RSLS N/A
- ALLR N/A
- EPS
- RSLS N/A
- ALLR N/A
- Revenue
- RSLS $8,006,000.00
- ALLR N/A
- Revenue This Year
- RSLS $52.80
- ALLR N/A
- Revenue Next Year
- RSLS N/A
- ALLR N/A
- P/E Ratio
- RSLS N/A
- ALLR N/A
- Revenue Growth
- RSLS N/A
- ALLR N/A
- 52 Week Low
- RSLS $0.30
- ALLR $0.61
- 52 Week High
- RSLS $29.00
- ALLR $25.47
- Technical
- Relative Strength Index (RSI)
- RSLS 38.68
- ALLR 52.91
- Support Level
- RSLS $9.75
- ALLR $1.01
- Resistance Level
- RSLS $11.65
- ALLR $1.10
- Average True Range (ATR)
- RSLS 1.23
- ALLR 0.10
- MACD
- RSLS 0.52
- ALLR -0.00
- Stochastic Oscillator
- RSLS 13.19
- ALLR 35.71
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.